Knight Cancer Institute

Medicine & Life Sciences

1. Neoplasms 100%
2. Prostatic Neoplasms 91%
3. Imatinib Mesylate 83%
4. Therapeutics 63%
5. Gastrointestinal Stromal Tumors 60%
6. Mutation 57%
7. Survival 56%
8. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 55%
9. Acute Myeloid Leukemia 45%
10. Protein-Tyrosine Kinases 42%
11. Cell Transplantation 41%
12. Phosphotransferases 41%
13. Castration 41%
14. Drug Therapy 39%
15. Transplants 36%
16. Leukemia 34%
17. Breast Neoplasms 31%
18. Clinical Trials 29%
19. Progression-Free Survival 28%
20. Genes 28%
21. Allogeneic Cells 27%
22. Bone Marrow 27%
23. Androgens 26%
24. Safety 25%
25. Docetaxel 25%
26. MDV 3100 25%
27. Recurrence 24%
28. Stem Cells 22%
29. Proteins 22%
30. Colorectal Neoplasms 21%
31. Multiple Myeloma 21%
32. Confidence Intervals 20%
33. Graft vs Host Disease 19%
34. Pharmaceutical Preparations 19%
35. B-Cell Chronic Lymphocytic Leukemia 19%
36. Prostate-Specific Antigen 19%
37. Placebos 18%
38. Biomarkers 18%
39. T-Lymphocytes 16%
40. Hematopoietic Stem Cells 16%
41. Phosphorylation 16%
42. Hematologic Neoplasms 16%
43. Neoplasm Metastasis 16%
44. Mortality 16%
45. Cell Line 16%
46. Adenocarcinoma 15%
47. Growth 15%
48. Transplantation 15%
49. Apoptosis 15%
50. Precursor Cell Lymphoblastic Leukemia-Lymphoma 14%
51. Thrombosis 14%
52. Tissue Donors 14%
53. Hemorrhage 14%
54. Randomized Controlled Trials 14%
55. Population 14%
56. Stem Cell Transplantation 14%
57. Unrelated Donors 14%
58. Non-Hodgkin's Lymphoma 14%
59. Homologous Transplantation 13%
60. Renal Cell Carcinoma 13%
61. Sarcoma 13%
62. Dasatinib 13%
63. Hematopoietic Stem Cell Transplantation 13%
64. In Vitro Techniques 13%
65. Myeloid Cells 13%
66. Tyrosine 13%
67. Lymphoma, Large B-Cell, Diffuse 13%
68. Radiotherapy 12%
69. Cytogenetics 12%
70. Prostate 12%
71. Leukemia, Myeloid, Chronic Phase 12%
72. pembrolizumab 12%
73. Calcium-Calmodulin-Dependent Protein Kinase Type 2 12%
74. Young Adult 11%
75. Calcitriol 11%
76. tisagenlecleucel 11%
77. Gene Expression 11%
78. Biopsy 11%
79. Philadelphia Chromosome 11%
80. Carcinoma 11%
81. Genome 11%
82. Mantle-Cell Lymphoma 11%
83. Sunitinib 11%
84. Androgen Receptors 11%
85. Quality of Life 10%
86. ponatinib 10%
87. Melanoma 10%
88. Blood Platelets 10%
89. B-Lymphocytes 10%
90. Receptor Protein-Tyrosine Kinases 10%
91. Lymphoma 10%
92. Thrombocytopenia 9%
93. Liver 9%
94. Incidence 9%
95. Transcriptome 9%
96. Anticoagulants 9%
97. Pancreatic Neoplasms 9%
98. src Homology Domains 9%
99. Systematic Reviews 9%